See more : Hanil Cement Co., Ltd. (300720.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Field Trip Health Ltd. (FTRP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Field Trip Health Ltd., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- SeaCo Ltd. (SEAOF) Income Statement Analysis – Financial Results
- National Cement Company (Public Shareholding Co.) (NCC.AE) Income Statement Analysis – Financial Results
- Corem Property Group AB (publ) (CORE-PREF.ST) Income Statement Analysis – Financial Results
- Bravura Solutions Limited (BVSFF) Income Statement Analysis – Financial Results
- Immutep Limited (IMM.AX) Income Statement Analysis – Financial Results
Field Trip Health Ltd. (FTRP)
About Field Trip Health Ltd.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 4.86M | 960.90K | 1.00K |
| Cost of Revenue | 9.15M | 1.54M | 9.40K |
| Gross Profit | -4.29M | -583.43K | -8.40K |
| Gross Profit Ratio | -88.27% | -60.72% | -840.30% |
| Research & Development | 7.31M | 3.42M | 193.19K |
| General & Administrative | 34.48M | 12.06M | 2.63M |
| Selling & Marketing | 3.23M | 1.63M | 305.71K |
| SG&A | 37.72M | 13.69M | 2.93M |
| Other Expenses | 3.71M | 1.34M | 139.98K |
| Operating Expenses | 48.74M | 18.45M | 3.27M |
| Cost & Expenses | 57.89M | 19.99M | 3.28M |
| Interest Income | 425.90K | 51.04K | 2.66K |
| Interest Expense | 1.10M | 303.30K | 22.56K |
| Depreciation & Amortization | 3.60M | 1.39M | 146.32K |
| EBITDA | -49.99M | -21.42M | -2.46M |
| EBITDA Ratio | -1,028.61% | -2,229.16% | -245,944.20% |
| Operating Income | -53.59M | -19.03M | -3.27M |
| Operating Income Ratio | -1,102.74% | -1,980.30% | -327,483.20% |
| Total Other Income/Expenses | -1.10M | -4.09M | 646.51K |
| Income Before Tax | -54.69M | -23.12M | -2.63M |
| Income Before Tax Ratio | -1,125.30% | -2,405.84% | -262,832.40% |
| Income Tax Expense | 1.10M | -3.79M | 669.07K |
| Net Income | -55.79M | -23.12M | -2.63M |
| Net Income Ratio | -1,147.86% | -2,405.84% | -262,832.40% |
| EPS | -8.44 | -3.50 | -0.35 |
| EPS Diluted | -8.44 | -3.50 | -0.35 |
| Weighted Avg Shares Out | 6.61M | 6.61M | 7.60M |
| Weighted Avg Shares Out (Dil) | 6.61M | 6.61M | 7.60M |
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the...
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US...
Field Trip Health Ltd. to Participate in H.C.
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip's Co-Founder and CEO, Joseph del Moral,...
3 Psychedelic Stocks to Play the Shroom Boom
Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.
9 Psychedelic Stocks to Watch For 2022
The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to...
Field Trip Health Ltd. to Participate in Upcoming Conferences in December 2021
TORONTO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at H.C. Wainwright's 2nd Annual...
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.
Field Trip Health Ltd.'s (FTRP) CEO Joseph del Moral on Q2 2022 Results - Earnings Call Transcript
Field Trip Health Ltd.'s (FTRP) CEO Joseph del Moral on Q2 2022 Results - Earnings Call Transcript
Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021
TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend...
Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET
TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the...
Source: https://incomestatements.info
Category: Stock Reports